<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04972227</url>
  </required_header>
  <id_info>
    <org_study_id>C6463-103</org_study_id>
    <nct_id>NCT04972227</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia</brief_title>
  <official_title>A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclerion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclerion Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of CY6463 when&#xD;
      administered to participants with stable schizophrenia who are on a stable antipsychotic&#xD;
      medication regimen&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to study drug discontinuation</measure>
    <time_frame>28 (Â±4) days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of CY6463</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter: area under the concentration-time curve from time zero (predose) to 24 hours postdose (AUC0-24)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: area under the concentration-time curve during a dosing interval (AUCtau)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: average concentration during a dosing interval (Cavg)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: maximum observed concentration (Cmax)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: time to maximum observed concentration (Tmax)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: minimum observed concentration (Cmin)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: apparent systemic clearance (CL/F)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: accumulation ratio based on a comparison of AUC values after single and multiple dosing (RAUC)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: accumulation ratio based on a comparison of Cmax values after single and multiple dosing (RCmax)</measure>
    <time_frame>up to Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>CY6463</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CY6463 once-daily (QD) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo QD for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CY6463</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>CY6463</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Provides written informed consent to participate in this study&#xD;
&#xD;
          2. Body mass index is between 18 to 40 kg/m2&#xD;
&#xD;
          3. Fluent English speaker&#xD;
&#xD;
          4. Diagnosed with schizophrenia at least 1 year ago&#xD;
&#xD;
          5. Psychiatrically stable schizophrenia with no more than moderate symptomatology&#xD;
&#xD;
          6. On a stable atypical antipsychotic regimen&#xD;
&#xD;
          7. Agrees to use effective contraception throughout the study and for at least 3 months&#xD;
             afterward&#xD;
&#xD;
          8. Agrees to avoid using tobacco/nicotine and caffeine for several hours at a time&#xD;
&#xD;
          9. Agrees to not participate in another study of a drug or device while in this study&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Was in another study of a drug in the past 2 months&#xD;
&#xD;
          2. Fails a drug/alcohol screen, including amphetamines, barbiturates, cocaine, marijuana,&#xD;
             methadone, methamphetamine, 3,4 methylenedioxymethamphetamine (MDMA), phencyclidine,&#xD;
             or nonprescribed benzodiazepines or opiates&#xD;
&#xD;
          3. Has had a recent heavy smoking habit (&gt;40 cigarettes/2 packs/day) or recently had&#xD;
             nicotine replacement therapy&#xD;
&#xD;
          4. Has significant heart disease&#xD;
&#xD;
          5. Has hemophilia or any other bleeding/platelet dysfunction condition&#xD;
&#xD;
          6. Has hepatitis or HIV&#xD;
&#xD;
        Additional inclusion and exclusion criteria apply, per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Chickering</last_name>
    <role>Study Director</role>
    <affiliation>Cyclerion Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meghan Bratton</last_name>
    <phone>857-338-3339</phone>
    <email>mbratton@cyclerion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Chickering</last_name>
    <phone>857-338-3310</phone>
    <email>jchickering@cyclerion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Benzie</last_name>
      <phone>844-424-9494</phone>
      <email>jacobbenzie@cnstrial.com</email>
    </contact>
    <investigator>
      <last_name>David Walling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Reynolds</last_name>
      <phone>833-427-7626</phone>
      <email>mreynolds@hritrials.com</email>
    </contact>
    <investigator>
      <last_name>Elan Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive Impairment Associated with Schizophrenia</keyword>
  <keyword>CIAS</keyword>
  <keyword>CY6463</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

